PRINCIPLES OF CHEMOTHERAPY IN CANCER TREATMENT
Keywords:
chemotherapy, oncological diseases, cytostatic agents, combination therapy, neoadjuvant and adjuvant therapy, drug resistance, toxicity, targeted therapy, immunotherapy.Abstract
Chemotherapy is one of the principal methods of treating oncological diseases: the drugs spread through the bloodstream throughout the body and act on both the primary tumor and metastases. This article analyzes the mechanisms of action of the main groups of cytostatic agents, namely alkylating agents, antimetabolites, topoisomerase inhibitors, and antitubulin agents, in relation to the phases of the cell cycle. The principles of combination regimens and the aims and effectiveness of neoadjuvant and adjuvant chemotherapy are described. Particular attention is paid to the mechanisms of drug resistance in tumor cells, including the Goldie–Coldman hypothesis. The main toxic complications, such as bone marrow suppression, nausea, cardiotoxicity, and neurotoxicity, and ways of preventing them are also considered. The combination of chemotherapy with targeted therapy and immunotherapy is discussed. The findings may be useful for individualizing treatment.References
1.Chabner B.A., Longo D.L. (eds.). Cancer Chemotherapy, Immunotherapy and Biotherapy: Principles and Practice. 6th ed. Wolters Kluwer, 2019.
2.DeVita V.T., Lawrence T.S., Rosenberg S.A. (eds.). DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. Wolters Kluwer.
3.Brunton L.L., Knollmann B.C. (eds.). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill, 2023.
4.Skipper H.E., Schabel F.M., Wilcox W.S. Experimental evaluation of potential anticancer agents. XIII. Cancer Chemother Rep. 1964;35:1-111.
5.Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11-12):1727-1733.
6.Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
7.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
8.Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879.
9.Hesketh P.J., et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782-2797.
10.International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15(2):594-603.